ibat

Elobixibat (A 3309) is an inhibitor of the ileal bile acid transporter (IC50: 0.13 nM, 0.53 nM, and 5.8 nM for mouse, human, and canine IBAT). Elobixibat can be used in studies about chronic idiopathic constipation.

Odevixibat (A4250) is an effective, selective and orally active ileal bile acid transporter inhibitor. Odevixibat has the potential for the treatment of primary biliary cirrhosis. Odevixibat reduces cholestatic liver and bile duct injury in mice model.

S-8921 is an inhibitor of ileal Na+/bile acid cotransporter.

Maralixibat Chloride (LUM001 chloride), an apical, sodium-dependent, bile acid transport inhibitor, prevents enterohepatic bile acid recirculation.

Octimibate (Octimibato) is a non-prostaglandin platelet aggregation inhibitor and cyclic prostaglandin agonist.Octimibate is used in the treatment of cardiovascular disease and can be used to study atherosclerosis and thrombosis.

Ritivixibat is an ileal bile acid transporter (IBAT) inhibitor and bile acid modulator. It is utilized in research related to cardiovascular diseases, fatty acid metabolism disorders, glucose utilization abnormalities, gastrointestinal conditions, and liver diseases.

Elobixibat hydrate, a potent inhibitor of the ileal bile acid transporter (IBAT), exhibits IC50 values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human, mouse, and canine IBAT, respectively. It is utilized in the research of chronic idiopathic constipation (CIC).

(S)-Elobixibat is the S-isomer of Elobixibat. It is an orally active inhibitor of Apical Sodium-Dependent Bile (IBAT) and can reduce LDL cholesterol, increase serum GLP-1, and promote colonic motility. This compound shows potential for treating metabolic syndrome and can be studied for constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.

Elobixibat-D5 is a deuterated compound of Elobixibat. Elobixibat (T15209) has a CAS number of 439087-18-0. Elobixibat (T15209) is an inhibitor of the ileal bile acid transporter (IC50: 0.13 nM, 0.53 nM, and 5.8 nM for mouse, human, and canine IBAT). Elobixibat (T15209) can be used in studies about chronic idiopathic constipation.

Volixibat is a highly selective and competitive apical sodium-dependent bile acid transporter inhibitor. Volixibat has the potential for treatment for non-alcoholic steatohepatitis.

Epibatidine is an agonist of α7nACh with a Kd value of 100 nM. It is utilized in research related to Alzheimer's disease, Parkinson's disease, and schizophrenia.

Epibatidine 2HCl is a potent nicotinic agonist.

Locicortolone dicibate is a synthetic glucocorticoid corticosteroid which was never marketed.

Linerixibat (GSK2330672) is a highly effective, nonabsorbable ASBT inhibitor (IC50: 42 ± 3 nM) that can lower glucose in an animal model of type 2 diabetes and demonstrates excellent developability properties.

Eptifibatide (Eptifibatide Acetate), an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class, is a cyclic heptapeptide constructed from 6 amino acids and a mercaptopropionyl residue.

Futibatinib (TAS-120) is an orally active, potent, selective, highly bioavailable, and irreversible FGFR inhibitor with IC50 values ​​of 3.9, 1.3, 1.6, and 8.3 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. [2]

Eptifibatide acetate (148031-34-9 free base) (Eptifibatide acetate) , an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class, is a cyclic heptapeptide constructed from 6 amino acids and a mercaptopropionyl residue.

Barixibat is a bile acid transport inhibitor.

Paclitaxel Ceribate is a mitotic inhibitor used in cancer chemotherapy.

Sodium erythorbate (Eribate N) is used as an antioxidant and preservative.

Sofiniclin is an nAChR agonist with potential for non-stimulant therapeutic research on attention deficit disorders.

264W94 is a robust inhibitor of the ileal bile acid transporter (IBAT) and a novel agent for reducing cholesterol levels. It exhibits CYP7A1 induction and demonstrates significant antilipemic activity.